Neuromyopathy caused by long term colchicine therapy
- 주제(키워드) colchicine , toxicity , muscular disease , polyneuropathies
- 주제(기타) Clinical Neurology
- 설명문(일반) [Park, Hyung Jun] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Neurol, Kangnung, South Korea; [Lee, Hyung-Soo] Presbyterian Med Ctr, Dept Neurol, Jeonju, South Korea; [Koo, Heasoo] Seonam Hosp, Dept Pathol, Seoul, South Korea; [Han, Soo Jeong] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Rehabil Med, Seoul, South Korea; [Choi, Euno] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Pathol, Seoul, South Korea; [Lee, Chan Young; Lee, Seung Ah; Park, Kee Duk] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Neurol, Seoul, South Korea; [Choi, Young-Chul] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 ASEAN NEUROLOGICAL ASSOC
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000159964
- 본문언어 영어
초록/요약
Colchicine-induced neuromyopathy is an extremely rare complication, and can develop in the setting of acute overdose or chronic administration in therapeutic doses. A 72-year-old man presented with proximal muscle weakness and myalgia. He had angina pectoris and Behcet's disease, leading to the treatment of colchicine (1.2 mg daily for about 6 years), cyclosporine, methylprednisolone, simvastatin, and aspirin. A biceps brachii muscle biopsy was performed and electron microscopic examination revealed scattered autophagic vacuoles. He was initially treated with steroid pulse therapy. However, muscle weakness did not improve. After the discontinuation of colchicine, muscle power and myalgia improved steadily. There should be heightened awareness of colchicine-induced neuromyopathy because that clinical suspicion is the most important diagnostic clue, and termination of colchicine is the only treatment.
more